Antiinflamatórios não-esteroidais (AINEs) são muito utilizados para o alívio da dor. Estudos indicam que 1 em 7 pacientes com doenças inflamatórias crônicas usam AINEs e que 1 em 5 pessoas usam AINEs para dores agudas. Os AINEs inibem a cicloxigenase (COX-1 e COX-2) ou seletivamente a COX-2, e apesar de sua excelente ação antiinflamatória e analgésica, muitos são os efeitos colaterais. Problemas gastrointestinais (GI) são a queixa mais comum para os AINEs convencionais, que também são associados a apoptose de diferentes tipos celulares. Os COX-2 seletivos apresentam menos problemas GI, mas seu uso tem sido questionado pelo risco de trombose e enfarto do miocárdio. Todos os AINEs parecem interferir no processo de cicatrização, embora os resultados dos estudos realizados apresentem-se conflitantes. Uma vez que os AINEs são utilizados por grande número de pessoas, o objetivo do nosso trabalho foi avaliar os efeitos dessa medicação sobre o tecido epitelial e durante o processo de cicatrização. Ratos Wistar foram tratados diariamente com AINEs convencional (diclofenaco, 3mg/Kg) ou um COX-2 seletivo (Celecoxibe, 1mg/Kg) por períodos de 7 e 14 dias. O controle foi feito com animais da mesma idade e peso não submetidos ao tratamento com AINEs. Após 7 dias, em todos os animais, controles e tratados, foram realizadas feridas cirúrgicas (4cm de diâmetro) no dorso depilado, sob anestesia com Tribromoetanol. Foram analisados, histológica e histometricamente, os epitélios da mucosa bucal, e a área de cicatrização (3 e 7 dias pós-cirurgia). Os resultados obtidos foram tabelados para avaliação estatística apropriada. No geral foi possível observar que todos os AINEs provocaram alterações com o seu uso agudo, no entanto para os inibidores seletivos da COX- 2 houve uma tendência à normalização com o uso crônico, não observada com o uso do AINE convencional. Na avaliação da cicatrização foi possível observar que os AINEs convencionais provocaram um pequeno atraso no processo de cicatrização, o que não foi observado com o uso de AINE seletivo para COX-2. Foi possível concluir que é necessário cautela em pacientes que fazem uso de AINEs, por provocarem alterações significativas no epitélio bucal, sendo os convencionais os que apresentam alterações mais significativas principalmente a longo prazo / Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain relief mostly in inflammatory chronic diseases. One in 7 patients with chronic inflammatory diseases uses NSAIDs, 1 in 5 uses NSAIDs for acute pain. NSAIDs may inhibit cyclooxygenase (COX-1 and COX-2) or COX-2 selectively, and despite their excellent anti-inflammatory and analgesic action, there are many side effects related. Gastrointestinal (GI) problems are the most commmon complaint for conventional NSAIDs, wich are also associated with different cell types apoptosis. The COX-2 selective NSAIDs have less GI problems, but may be associated to risks of cardiovascular events. All of NSAIDs seems to interfere with wound healing, although studies results may show conflicting results. Since NSAIDs are used by large numbers of people, the aim of this study was to evaluate the effects of this medication on the epithelial tissue and during wound healing process. Wistar rats were treated daily with conventional NSAIDs (diclofenac, 3mg/Kg) or selective COX-2 (celecoxib, 1mg/Kg) for a period of 7-14 days. The control group was animals of similar age and weight not treated with NSAIDs. After 7 days in all the animals, control and treated, were made surgical wounds (4cm in diameter) on the shaved back under anesthesia with Tribromoethanol. Oral mucosa and wound healing were histological and histometrically analyzed (3 and 7 days after surgery). The results received appropriated statistical evaluation. It was possible to observe that both NSAIDs lead to changes with acute use, but only selective COX-2 inhibitors tends to get back to normal parameters with long lasting use. Related to wound healing, it was possible to verify that conventional NSAIDs was associated to a slightly delay in wound healing process, which was not observed with selective COX-2 NSAIDs use. It was possible to conclude that caution is needed with the use of NSAIDs. They cause significant changes in oral epithelium and the convenional one causes most signifcant changes with long term use

Antiinflamatórios não-esteroidais (AINEs) são muito utilizados para o alívio da dor. Estudos indicam que 1 em 7 pacientes com doenças inflamatórias crônicas usam AINEs e que 1 em 5 pessoas usam AINEs para dores agudas. Os AINEs inibem a cicloxigenase (COX-1 e COX-2) ou seletivamente a COX-2, e apesar de sua excelente ação antiinflamatória e analgésica, muitos são os efeitos colaterais. Problemas gastrointestinais (GI) são a queixa mais comum para os AINEs convencionais, que também são associados a apoptose de diferentes tipos celulares. Os COX-2 seletivos apresentam menos problemas GI, mas seu uso tem sido questionado pelo risco de trombose e enfarto do miocárdio. Todos os AINEs parecem interferir no processo de cicatrização, embora os resultados dos estudos realizados apresentem-se conflitantes. Uma vez que os AINEs são utilizados por grande número de pessoas, o objetivo do nosso trabalho foi avaliar os efeitos dessa medicação sobre o tecido epitelial e durante o processo de cicatrização. Ratos Wistar foram tratados diariamente com AINEs convencional (diclofenaco, 3mg/Kg) ou um COX-2 seletivo (Celecoxibe, 1mg/Kg) por períodos de 7 e 14 dias. O controle foi feito com animais da mesma idade e peso não submetidos ao tratamento com AINEs. Após 7 dias, em todos os animais, controles e tratados, foram realizadas feridas cirúrgicas (4cm de diâmetro) no dorso depilado, sob anestesia com Tribromoetanol. Foram analisados, histológica e histometricamente, os epitélios da mucosa bucal, e a área de cicatrização (3 e 7 dias pós-cirurgia). Os resultados obtidos foram tabelados para avaliação estatística apropriada. No geral foi possível observar que todos os AINEs provocaram alterações com o seu uso agudo, no entanto para os inibidores seletivos da COX- 2 houve uma tendência à normalização com o uso crônico, não observada com o uso do AINE convencional. Na avaliação da cicatrização foi possível observar que os AINEs convencionais provocaram um pequeno atraso no processo de cicatrização, o que não foi observado com o uso de AINE seletivo para COX-2. Foi possível concluir que é necessário cautela em pacientes que fazem uso de AINEs, por provocarem alterações significativas no epitélio bucal, sendo os convencionais os que apresentam alterações mais significativas principalmente a longo prazo / Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for pain relief mostly in inflammatory chronic diseases. One in 7 patients with chronic inflammatory diseases uses NSAIDs, 1 in 5 uses NSAIDs for acute pain. NSAIDs may inhibit cyclooxygenase (COX-1 and COX-2) or COX-2 selectively, and despite their excellent anti-inflammatory and analgesic action, there are many side effects related. Gastrointestinal (GI) problems are the most commmon complaint for conventional NSAIDs, wich are also associated with different cell types apoptosis. The COX-2 selective NSAIDs have less GI problems, but may be associated to risks of cardiovascular events. All of NSAIDs seems to interfere with wound healing, although studies results may show conflicting results. Since NSAIDs are used by large numbers of people, the aim of this study was to evaluate the effects of this medication on the epithelial tissue and during wound healing process. Wistar rats were treated daily with conventional NSAIDs (diclofenac, 3mg/Kg) or selective COX-2 (celecoxib, 1mg/Kg) for a period of 7-14 days. The control group was animals of similar age and weight not treated with NSAIDs. After 7 days in all the animals, control and treated, were made surgical wounds (4cm in diameter) on the shaved back under anesthesia with Tribromoethanol. Oral mucosa and wound healing were histological and histometrically analyzed (3 and 7 days after surgery). The results received appropriated statistical evaluation. It was possible to observe that both NSAIDs lead to changes with acute use, but only selective COX-2 inhibitors tends to get back to normal parameters with long lasting use. Related to wound healing, it was possible to verify that conventional NSAIDs was associated to a slightly delay in wound healing process, which was not observed with selective COX-2 NSAIDs use. It was possible to conclude that caution is needed with the use of NSAIDs. They cause significant changes in oral epithelium and the convenional one causes most signifcant changes with long term use

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications globally. There are generally two types: selective (COX-2) and traditional NSAIDs (COX-1). They are primarily used for the treatment of pain. They gained attention after a study about their basic mechanisms highlighted their toxicity. Several studies have reported an association between NSAIDs and risk of myocardial infarction (MI). However, the direction of the relationship is not conclusive. Further studies are needed to ascertain the direction of this relationship and evaluate the present situation with available drugs. Due to the seriousness of cardiovascular diseases as one of the leading cause of death, continuous monitoring of the NSAIDs-MI association is needed. The purpose of this dissertation was to investigate the association between NSAIDs and MI in a younger (30-64 years) Kentucky Medicaid population with a 12 year window of data. The three specific aims were: (1) to understand the characteristics of the Kentucky Medicaid population with respect to NSAID use: (2) to evaluate the NSAID-MI relationship with a 12 year follow-up in a young heavily-burdened population for cardiovascular diseases: and (3) to investigate the MI risk of meloxicam, celecoxib and naproxen compared to no exposure. A retrospective study was conducted employing data from January 1st 2000 and December 31st 2012. The data comprised demographic, prescription and medical files. Within this cohort, a nested case control study was conducted. Cases of MI were matched to four controls on race and gender. The results suggested that exposure to COX 2 presented an increased adjusted risk for MI (1.138(0.983, 1.318)). However, this risk was significantly increased for COX-2 only users compared to COX-1 only users (1.221 (1.03, 1.485)) and 30-40 year olds (1.600 (1.082, 2.367)). Meloxicam, celecoxib and naproxen compared to no exposure showed meloxicam presented a non-significant different risk for MI (1.26 (0.98, 1.63)) and celecoxib presented a significantly increased risk for MI (1.52 (1.26, 1.82)). This study considered pattern of use in determining continuous usage by looking at both continuous and sporadic users of NSAIDs and also considered patient switching patterns between classes of NSAIDs.

ABSTRACT The non-steroidal anti-inflammatory drug (NSAID), diclofenac, has been associated with a high risk for cardiovascular events in observational studies. However, majority of studies identifying this association were conducted when diclofenac was the only NSAID that could be obtained as a combination product (i.e., formulated with misoprostol). As a result, channelling bias might have resulted if prescribers selected the combination of diclofenac/misoprostol (Diclo-Miso) in patients with poor health status frequently than other NSAID products. The main purpose of this study was to identify evidence for channelling bias in a cohort of patients with coronary heart disease (CHD) prescribed NSAIDs. Three independent, retrospective analyses were carried out using Saskatchewan’s health administrative databases. Patients were eligible if they were hospitalized with CHD event between January 1, 1994 and December 31, 2008. In the first analysis, a time series was conducted to examine trends in the use of NSAIDs following discharge from original hospitalization. In the second analysis, multivariate logistic regression models were constructed to identify characteristics of patients prescribed with Diclo-Miso in comparison to single-entity diclofenac. Finally, a nested case-control study was conducted to examine the risk for recurrent myocardial infarction (MI)/ Unstable Angina (UA) or death among patients prescribed with Diclo-Miso versus single-entity diclofenac. For each case, up to five controls were matched by age and sex. Between 1994 and 2008, NSAIDs were used by 20.1% (3,099/15,393) of patients in the year following discharge from their original MI/UA hospitalization. Use of these agents was relatively stable until 2004 when the COX-2 selective agent rofecoxib was withdrawn from the market. Following this date (i.e., September 30, 2004), the use of Diclo-Miso and single-entity diclofenac appeared to follow different trends. However, available patient and disease specific factors could not explain diverging utilization trends. Further, no differences were observed in the risk of experiencing recurrent MI/UA between patients receiving Diclo-Miso (OR 0.88, 95% CI 0.72-1.08, p=0.22) or single-entity diclofenac (OR 0.78, 95% CI 0.60-1.00, p=0.06) versus patients not exposed to NSAIDs. Based on the study’s result, channelling bias does not appear to be a major threat to the analysis of cardiovascular toxicity of diclofenac products.

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for systemic control of acute and chronic pain and inflammation (Lin et ah, 2000:1129), but usage problems and side-effects that occur during the post-marketing phase of these drugs are well documented (Thiefin & Beaugerie, 2005:287). Following the demonstration of the value of anti-inflammatory therapy in diseases like rheumatoid arthritis (Boardman & Dudley Hart, 1967:268), new NSAIDs appeared on the market (Dieppe et al., 2004:867), and the indications steadily broadened from inflammatory diseases to almost any painful condition. Studies have indicated that NSAID-associated serious upper gastro-intestinal (GI) adverse events result in 103 000 hospitalisations (Bombardier, 2002:4) and 165 000 deaths per year in the United States. A study in South Africa in 2002 indicated that NSAID utilisation contributed considerably to the total cost of all medicine items from a medicine claim database in the private health care sector (Joubert, 2002:260). The objective of this study was to determine the prevalence and cost of non-steroid anti-inflammatory drugs in a section of the private health care sector, and specifically to determine the prevalence, usage and cost of Coxib (Specific cyclo-oxygenase-2 inhibitor) medicine items before and after the withdrawal of Vioxx® from the market in September 2004 (Merck, 2004). Data from two medicine claim databases for the years 2004, 2005 and 2006 (medicine claim database I) and the years 2005 and 2006 (medicine claim database M), were analysed by means of a retrospective drug utilisation review (DUR) study. The usage of Coxib medicine items was determined, and compared for the periods before and after the withdrawal of Vioxx® in September 2004. It was found that between 9 and 10.5 per cent of prescriptions dispensed through both medicine claim database I and medicine claim database M during the study period were NSAID prescriptions. NSAID medicine items on medicine claim database I represented between 3.9 % (R25 942 986) and 2.9 % (R8 073 034) of the total cost of all medicine items claimed from 2004 to 2006. NSAIDs represented 3.1 % (R58 290 412) and 2.8 % (R57 752 267) of the cost of all medicine items claimed through medicine claim database M during 2005 and 2006 respectively, indicating similar trends in the two medicine claim databases. The prevalence of Coxibs on medicine claim database I decreased from almost 20 % (47 938) in 2004 to 8.4 % (13 276) in 2005, but showed an increase again to 10.9 % (12 355) in 2006. The prevalence of both cyclo-oxygenase (COX) inhibitors, and Coxibs demonstrated a change during 1 September 2004 to 31 December 2004 when COX-inhibitors showed an increase in use, while Coxibs showed and almost equal but opposite trend with a decrease in use. This could possibly be related to perceptions of providers and public with regard to Coxibs and their related safety after the withdrawal of Vioxx® on 30 September 2004 (Merck, 2004) and other Coxibs such as Bextra® (FDA, 2005) in 2005 in USA. It is concluded that most patients who were using Coxibs before the withdrawal of Vioxx®, substituted Coxibs for COX-inhibitors, that are known for their possible gastro-intestinal side-effects. Recommendations for future research regarding NSAID use were also made, and included an investigation of the usage of Coxibs in different age groups, as well as the combination of NSAIDs with gastro-protective medicines in long-term use. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2009.

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for systemic control of acute and chronic pain and inflammation (Lin et ah, 2000:1129), but usage problems and side-effects that occur during the post-marketing phase of these drugs are well documented (Thiefin & Beaugerie, 2005:287). Following the demonstration of the value of anti-inflammatory therapy in diseases like rheumatoid arthritis (Boardman & Dudley Hart, 1967:268), new NSAIDs appeared on the market (Dieppe et al., 2004:867), and the indications steadily broadened from inflammatory diseases to almost any painful condition. Studies have indicated that NSAID-associated serious upper gastro-intestinal (GI) adverse events result in 103 000 hospitalisations (Bombardier, 2002:4) and 165 000 deaths per year in the United States. A study in South Africa in 2002 indicated that NSAID utilisation contributed considerably to the total cost of all medicine items from a medicine claim database in the private health care sector (Joubert, 2002:260). The objective of this study was to determine the prevalence and cost of non-steroid anti-inflammatory drugs in a section of the private health care sector, and specifically to determine the prevalence, usage and cost of Coxib (Specific cyclo-oxygenase-2 inhibitor) medicine items before and after the withdrawal of Vioxx® from the market in September 2004 (Merck, 2004). Data from two medicine claim databases for the years 2004, 2005 and 2006 (medicine claim database I) and the years 2005 and 2006 (medicine claim database M), were analysed by means of a retrospective drug utilisation review (DUR) study. The usage of Coxib medicine items was determined, and compared for the periods before and after the withdrawal of Vioxx® in September 2004. It was found that between 9 and 10.5 per cent of prescriptions dispensed through both medicine claim database I and medicine claim database M during the study period were NSAID prescriptions. NSAID medicine items on medicine claim database I represented between 3.9 % (R25 942 986) and 2.9 % (R8 073 034) of the total cost of all medicine items claimed from 2004 to 2006. NSAIDs represented 3.1 % (R58 290 412) and 2.8 % (R57 752 267) of the cost of all medicine items claimed through medicine claim database M during 2005 and 2006 respectively, indicating similar trends in the two medicine claim databases. The prevalence of Coxibs on medicine claim database I decreased from almost 20 % (47 938) in 2004 to 8.4 % (13 276) in 2005, but showed an increase again to 10.9 % (12 355) in 2006. The prevalence of both cyclo-oxygenase (COX) inhibitors, and Coxibs demonstrated a change during 1 September 2004 to 31 December 2004 when COX-inhibitors showed an increase in use, while Coxibs showed and almost equal but opposite trend with a decrease in use. This could possibly be related to perceptions of providers and public with regard to Coxibs and their related safety after the withdrawal of Vioxx® on 30 September 2004 (Merck, 2004) and other Coxibs such as Bextra® (FDA, 2005) in 2005 in USA. It is concluded that most patients who were using Coxibs before the withdrawal of Vioxx®, substituted Coxibs for COX-inhibitors, that are known for their possible gastro-intestinal side-effects. Recommendations for future research regarding NSAID use were also made, and included an investigation of the usage of Coxibs in different age groups, as well as the combination of NSAIDs with gastro-protective medicines in long-term use. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2009.

Orientador: Marco Antônio Alvarenga / Resumo: Na espécie equina, o embrião se movimenta no útero entre os dias 9 e 16 após a ovulação, o concepto apresenta uma forma esférica e se move constantemente no lúmen uterino mediante contrações miometriais, produzidas por estimulação química da vesícula embrionária. O deslocamento embrionário durante este período é essencial para o reconhecimento materno da gestação. Este longo período de estímulo garante que o embrião produza sinais anti-luteolíticos no endométrio, evitando a luteólise. Após 17 dias, a vesícula embrionária cessa a mobilidade e ocorre a fixação em um dos cornos. Durante a mobilidade, o embrião produz prostaglandinas PGE-2, PGF-2α e PGI-2. Se houver uma falha durante a migração embrionária, o reconhecimento materno da gestação pode ser afetado e consequentemente há lise do corpo lúteo, resultando na perda precoce da prenhes. O uso do anti-inflamatório flunixin meglumine imediatamente após a transferência do embrião é amplamente utilizado para prevenir uma reação inflamatória local, a luteólise e a perda embrionária precoce. No entanto, de acordo com a literatura, o ácido mefenâmico causa menos efeitos sobre a mobilidade embrionária e aumenta as taxas de gestação. O objetivo deste estudo foi elucidar o efeito do ácido mefenâmico sobre a mobilidade embrionária em éguas. Foram selecionadas 10 éguas para o estudo. Após a confirmação da gestação com ultrassom transretal, a mobilidade embrionária foi avaliada por ultrassonografia em série (a cada 5 minutos) durante 1 h... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: In the equine specie, the embryo moves in the uterus between days 9 and 16 after ovulation, the conceptus presents a spherical shape and moves constantly in the uterine lumen through myometrial contractions, produced by chemical stimulation of the embryonic vesicle. Embryonic displacement during this period is essential for maternal recognition of pregnancy. This long stimulus period ensures that the embryo produces anti-luteolytic signals to the endometrium, avoiding the luteolysis. After 17 days the embryonic vesicle stops the mobility and occurs the fixation in one of the horns. During mobility, the embryo produces prostaglandins PGE-2, PGF, and PGI-2. If there is a failure during embryo migration the maternal recognition of pregnancy may be affected and consequently lysis of corpus luteum, resulting in the early pregnancy loss. The use of the anti-inflammatory flunixin meglumine immediately after the embryo transfer is widely used in order to prevent a local inflammatory reaction, luteolysis, and early embryonic loss. However, according to the literature, mefenamic acid cause less effects on embryonic mobility and increases pregnancy rates. The objective of this study was to elucidate the effect of mefenamic acid on embryonic mobility in mares. There were selected 10 mares for the study. After confirmation of pregnancy with transrectal ultrasound, the embryo mobility was evaluated by serial ultrasonography (every 5 minutes) during 1 hour. This examination was considered t... (Complete abstract click electronic access below) / Mestre

Master of Science / Department of Clinical Sciences / Gregory F. Grauer / Prostaglandins play many important roles in the kidney including regulation of renal blood flow, glomerular filtration, renin release, and sodium excretion. Upon activation of the renin angiotensin aldosterone system (RAAS), prostaglandin upregulation becomes critical to offset the vasoconstrictive effects of norephinephrine, angiotensin II, and vasopressin. Nonsteroidal anti-inflammatory drugs (NSAIDs) produce both their beneficial and detrimental effects through inhibition of the cyclooxygenase enzyme and subsequent interference with prostaglandin production. Healthy canine kidneys express both COX-1 and COX-2, although basal COX-2 expression in dogs is significantly higher than in other species. Nonsteroidal anti-inflammatory drugs that spare COX-1 have exhibited less gastrointestinal toxicity, but no NSAID has been proven safe for the kidney. The kidney is the organ with the second highest reports of adverse drug events, which is usually manifested as functional changes. However, structural changes including renal papillary necrosis, can occasionally be observed. Dogs with chronic kidney disease could be expected to be at increased risk for NSAID-related adverse drug effects. As nephrons and renal reserve are lost in chronic kidney disease, the canine kidney becomes more dependent on COX-2 for production of prostaglandins. Inasmuch as the prevalence of both CKD and OA increases with age, it is expected that many dogs being treated with NSAIDs for OA will have loss of renal reserve and/or early stage CKD. If administration of an NSAID is required for long term treatment of osteoarthritis, frequent monitoring of blood pressure and renal parameters, as well as hepatic enzymes are recommended.

Submitted by Rosangela Silva (rosangela.silva3@unioeste.br) on 2018-05-25T13:06:30Z No. of bitstreams: 2 Leilaine Elisa Romano.pdf: 1471293 bytes, checksum: 6b285121668b66c678267cc210609ebe (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2018-05-25T13:06:30Z (GMT). No. of bitstreams: 2 Leilaine Elisa Romano.pdf: 1471293 bytes, checksum: 6b285121668b66c678267cc210609ebe (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2018-03-05 / Emerging contaminants can be defined as chemical compounds in commercial products, which can be recorded in environmental and biological matrices, although they do not have legal regulations yet regarding their disposal and presence in the environment. Drugs as emerging pollutants have stood out among researches due to their impact on the environment and health, for example by impairing surface water quality and so its consumption. The presence of these substances into the environment occurs because of their use to treat diseases in humanbeings and animals. Drugs are, so, realeased by excretion, and also by effluents into water bodies. The consumption of non-steroidal anti-inflammatory drugs by the population has been quite high due to their analgesic and antipyretic properties. Thus, this study aimed at evaluating the presence of diclofenac sodium as an anti-inflammatory drug in river of Cascavel city, Paraná. Water samples were collected from the Cascavel river, from July to November, 2017. Samples were pH adjusted, filtrated and solid phase extracted with SPE cartridges. After elution, the analytes were analyzed by High Performance Liquid Chromatography, using C18 column and UV-VIS detector. The method underwent a validation study, so that linearity, limit of detection and quantification, intermediate precision and recovery were analyzed. The data show that the studied parameters are in accordance with the current legislation on analytical validation. The samples results, analyzed by the proposed method, showed some ranging from 0.70 to 1.06 μg.L-1. Chapter I introduces the scientific paper containing the chromatographic method optimization to determine diclofenac sodium in environmental samples as well as the results concerning its occurrence in the studied samples. / Contaminantes emergentes podem ser definidos como compostos químicos presentes em produtos comerciais, que podem ser encontrados em matrizes ambientais e biológicas e que ainda não possuem regulamentação legal quanto ao descarte e à presença no ambiente. Fármacos como contaminantes emergentes têm ganhado destaque entre as pesquisas devido ao impacto que podem causar no meio ambiente e na saúde, a partir, por exemplo, do comprometimento da qualidade das águas superficiais e para consumo. A introdução destas substâncias no ambiente ocorre por uso no tratamento de doenças em humanos e animais, as quais são, então, liberadas por excreção, e também pelo lançamento de efluentes em corpos hídricos. O consumo de fármacos anti-inflamatórios não esteroides pela população é bastante elevado devido também às suas propriedades analgésicas e antipiréticas. Por conseguinte, o objetivo deste trabalho foi avaliar a presença do fármaco anti-inflamatório diclofenaco sódico em águas superficiais de rio na cidade de Cascavel-PR. Foram coletadas amostras de água no rio Cascavel no período de agosto a novembro de 2017. As amostras passaram por ajuste no pH, filtração e extração em fase sólida com cartuchos SPE. Após a eluição, os analitos foram analisados por Cromatografia Líquida de Alta Eficiência, utilizando coluna C18 e detector UV-VIS. O método passou por estudo de validação, em que foram analisados a linearidade, o limite de detecção e quantificação, a precisão intermediária e a recuperação. Os dados registram que tais parâmetros estão em conformidade com a legislação vigente sobre validação analítica. Os resultados das amostras analisadas pelo método prosposto apresentaram variação de 0,70 a 1,06 μg.L-1. O Capítulo I apresenta o artigo científico contendo a otimização de um método cromatográfico para determinação de diclofenaco sódico em amostras ambientais e os resultados em termos da ocorrência deste nas amostras estudadas.

La fièvre est la première cause de consultation et d’exposition médicamenteuse chez l’enfant. Les principales molécules utilisées dans cette indication sont le paracétamol et un anti-inflammatoire non stéroïdien (AINS), l’ibuprofène. L’objectif général de cette thèse était de produire des connaissances nouvelles sur les pratiques des parents et des professionnels de santé pour la prise en charge symptomatique, notamment médicamenteuse, de la fièvre chez l’enfant. Les données étaient issues d’une étude transversale nationale menée entre 2007 et 2008, où 1534 médecins généralistes, pédiatres et pharmaciens (taux de participation 13%) ont inclus 6596 enfants avec une fièvre < 48h. Les analyses ont notamment utilisé des modèles multi-niveau multivariés. Les connaissances et les pratiques des parents et des professionnels étaient fréquemment discordantes par rapport aux recommandations, notamment pour la mise en œuvre des mesures antipyrétiques. Les principaux déterminants de pratiques non concordantes aux recommandations étaient un faible niveau d’études des parents, un âge élevé de l’enfant et la formation initiale de généraliste du professionnel consulté. Pour les enfants ayant reçu du paracétamol, un recours important aux suppositoires a été observé, y compris chez les enfants âgés et sans vomissement. Les parents utilisaient beaucoup plus d’AINS que les professionnels de santé et ce gradient augmentait dans des situations potentiellement à risque d’effet indésirable. Nos résultats montrent la nécessité d’actions d’éducation à la santé et de formation médicale continue pour la prise en charge de la fièvre de l’enfant et permettent de cerner les messages prioritaires. / Fever is the first reason for consultation and drug treatment in children in primary care. Main drugs used in this indication are acetaminophen and a non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen. The objective of this thesis was to produce new knowledge on parents’ and healthcare professionals' (HPs) practices for the symptomatic treatment of fever in children with a focus on drug treatments. We used data from an observational, cross-sectional, national study performed from October 2007 to June 2008, where 1,534 general practitioners, primary care pediatricians, and pharmacists (participation rate 13%) included 6,596 children with fever < 48 hr. Analyses used notably multivariate multilevel models.Knowledge and practices of parents and HPs were frequently discordant with recommendations, notably for antipyretic measures. The main determinants of discordant practices were a low parental educational level, an older child’s age and the healthcare professional being a general practitioner. Among children who received acetaminophen, a large use of suppositories has been observed, including for non-vomiting and/or older children. Parents used more NSAIDs than HPs, and this gradient increased in clinical conditions potentially at risk of adverse effect. Our results highlight the need for health education interventions and continuing medical training on fever management in children, and enable to identify priority messages.